Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 11/20 | 0.59 |
| ▸ | IP6K1 | Q92551 | 4/20 | 0.54 |
| ▸ | KDM4A | O75164 | 1/20 | 0.51 |
| ▸ | KDM4B | O94953 | 1/20 | 0.51 |
| ▸ | KDM5C | P41229 | 1/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.51 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.51 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.50 |
| ▸ | PIM1 | P11309 | 2/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.50 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6836452 | 0.85 | PARP1 (0.59) | PARP1IP6K1KDM4AKDM4BKDM5C | |
| SCHEMBL7657502 | 0.78 | PARP1 (0.59) | PARP1IP6K1KDM4AKDM4BKDM5C | |
| SCHEMBL669366 | 0.78 | PARP1 (0.59) | PARP1IP6K1KDM4AKDM4BKDM5C | |
| SCHEMBL7970843 | 0.78 | PARP1 (0.59) | PARP1IP6K1KDM4AKDM4BKDM5C | |
| SCHEMBL2427721 | 0.77 | PARP1 (0.62) | PARP1IP6K1CHEK1PIM1AKT1 | |
| SCHEMBL29709603 | 0.74 | PARP1 (1.00) | PARP1IP6K1CHEK1PIM1AKT1 | |
| SCHEMBL2191067 | 0.74 | PARP1 (1.00) | PARP1IP6K1CHEK1PIM1AKT1 | |
| SCHEMBL6364139 | 0.74 | PARP1 (0.50) | PARP1IP6K1KDM4AKDM4BKDM5C | |
| SCHEMBL21331974 | 0.74 | PARP1 (0.54) | PARP1IP6K1KDM4AKDM4BKDM5C | |
| SCHEMBL6769666 | 0.74 | IP6K1 (0.50) | PARP1IP6K1KDM4AKDM4BKDM5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010027197-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | BRIDGES ALEXANDER JAMES (US) | 2001-10-04 | — | — | US | claimed |
| CN-111247152-B | Cyclic iminopyrimidine derivatives as kinase inhibitors | 璧辰医药技术股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-11932647-B2 | Cyclic iminopyrimidine derivatives as kinase inhibitors | ABM THERAPEUTICS CORPORATION (US) | 2024-03-19 | — | — | US | disclosed |
| EP-3684772-B1 | CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ABM THERAPEUTICS CORP (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230121116-A1 | USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCERS WITH NRG1 FUSIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-04-20 | — | — | US | disclosed |
| EP-4097140-A1 | USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCERS WITH NRG1 FUSIONS | Board of Regents, The University of Texas System (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-115427456-A | Use of quinazoline-based tyrosine kinase inhibitors in the treatment of cancer with NRG1 fusion | 得克萨斯州大学系统董事会 | 2022-12-02 | — | — | CN | disclosed |
| US-20220251089-A1 | CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | ABM THERAPEUTICS CORPORATION (CA) | 2022-08-11 | — | — | US | disclosed |
| US-20220194940-A1 | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2022-06-23 | — | — | US | disclosed |
| US-20220194940-A1 | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2022-06-23 | — | — | US | disclosed |
| US-6344459-B1 | TREATING CANCER, RESTENOSIS, ATHEROSCLEROSIS, ENDOMETRIOSIS, AND PSORIASIS | WARNER-LAMBERT COMPANY | 2002-02-05 | — | — | US | disclosed |
| US-6313292-B1 | REACTION FROM 5-AMINO-2-FLUOROPYRIDINE; AMINATION, CYCLIZATION, CHLORINATION, SALT FORMATION, DECHLORINATION, DEBLOCKING | WARNER-LAMBERT COMPANY | 2001-11-06 | — | — | US | disclosed |
| US-20010027197-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | BRIDGES ALEXANDER JAMES (US) | 2001-10-04 | — | — | US | disclosed |
| US-6265410-B1 | ANTICARCINOGENIC AGENTS | WARNER-LAMBERT COMPANY | 2001-07-24 | — | — | US | disclosed |
| EP-1067123-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-01-10 | — | — | EP | disclosed |
| US-6084095-A | INCLUDING 6-AMINO-4-(3-BROMOANILINO)PYRIDO(3,2-D)PYRIMIDINE; 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO (3,2-D)PYRIMIDINE; AND 4-(3-BROMOANILINO)-6-METHYLAMINOPYRIDO(3,2-D)PYRIMIDINE; USEFUL IN TREATING PROLIFERATIVE DISEASES SUCH AS CANCER | WARNER-LAMBERT COMPANY (US) | 2000-07-04 | — | — | US | disclosed |
| US-5654307-A | ANTICARCINOGENIC AGENTS, ANTIARTHRITIC AGENT, SKIN DISORDERS | WARNER-LAMBERT COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| WO-1997026259-A1 | IMPROVED PROCESS FOR PREPARING 4,6-DISUBSTITUTED PYRIDO[3,4-d]PYRIMIDINES | WARNER-LAMBERT COMPANY (US) | 1997-07-24 | — | — | WO | disclosed |
| EP-0742717-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1996-11-20 | — | — | EP | disclosed |
| WO-1995019774-A1 | BICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY | WARNER-LAMBERT COMPANY (US) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027197-A1 | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family | EGFR, ERBB2, ERBB3 | PARP1 4178/4885IP6K1 1521/4885KDM4A 2593/4885 |
| US-20220194940-A1 | HETEROCYCLIC INHIBITORS OF TYROSINE KINASE | ERBB2, ERBB3, EGFR | PARP1 1262/4885IP6K1 637/4885KDM4A 3367/4885 |
| US-20220251089-A1 | CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | BRAF, CDK4, RAF1 | PARP1 276/4885IP6K1 130/4885KDM4A 2046/4885 |
| US-20230121116-A1 | USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCERS WITH NRG1 FUSIONS | ERBB2, ERBB3, ERBB4 | PARP1 3087/4885IP6K1 1884/4885KDM4A 2854/4885 |
| US-11932647-B2 | Cyclic iminopyrimidine derivatives as kinase inhibitors | BRAF, CDK4, RAF1 | PARP1 276/4885IP6K1 130/4885KDM4A 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.